Article ; Online: Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy.
2024 Volume 13, Issue 7, Page(s) e6989
Abstract: The N6-methyladenosine (m6A) RNA modification has gained significant prominence as a new layer of regulatory mechanism that governs gene expression. Over the past decade, various m6A regulators responsible for introducing, eliminating, and recognising ... ...
| Abstract | The N6-methyladenosine (m6A) RNA modification has gained significant prominence as a new layer of regulatory mechanism that governs gene expression. Over the past decade, various m6A regulators responsible for introducing, eliminating, and recognising RNA methylation have been identified. Notably, these m6A regulators often exhibit altered expression patterns in cancer, occasionally offering prognostic value. Nonetheless, the complex roles of these regulators in human cancer pathology remain enigmatic, with conflicting outcomes reported in different studies.In recent years, a multitude of inhibitors and activators targeting m6A regulators have been reported. Several of these compounds have demonstrated promising efficacy in both in vitro and in vivo cancer models. These findings collectively underscore the dynamic landscape of m6A regulation in cancer biology, revealing its potential as a therapeutic target and prognostic indicator. |
|---|---|
| MeSH term(s) | Humans ; Adenosine/therapeutic use ; RNA Methylation ; RNA/genetics ; Neoplasms/drug therapy ; Neoplasms/genetics |
| Chemical Substances | Adenosine (K72T3FS567) ; RNA (63231-63-0) |
| Language | English |
| Publishing date | 2024-03-28 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 2659751-2 |
| ISSN | 2045-7634 ; 2045-7634 |
| ISSN (online) | 2045-7634 |
| ISSN | 2045-7634 |
| DOI | 10.1002/cam4.6989 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.